Verastem Oncology is a part of the healthcare sector. It is a commercial-stage company focused on discovering and developing drugs to aid patients suffering from cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The Company's product pipeline candidate, defactinib, is a focal adhesion kinase inhibitor in development for the treatment of cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.
| Website: | www.verastem.com |
| Email: | rgagnon@verastem.com |
| Main Phone: | +1 781 292-4200 |
| Address: | 117 Kendrick Street |
| Address 2: | Suite 500 |
| State: | MA |
| City / Town: | Needham |
| Country: | USA |
| Postal Code: | 02494 |
| Exchange: | NSD |
| CEO: | Robert Forrester |
| Employees: | 169 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Gathering Data... Please wait Verastem Oncology is a part of the healthcare sector. It is a commercial-stage company focused on discovering and developing drugs to aid patients suffering from cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The Company's product pipeline candidate, defactinib, is a focal adhesion kinase inhibitor in development for the treatment of cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.
| Website: | www.verastem.com |
| Email: | rgagnon@verastem.com |
| Main Phone: | +1 781 292-4200 |
| Address: | 117 Kendrick Street |
| Address 2: | Suite 500 |
| State: | MA |
| City / Town: | Needham |
| Country: | USA |
| Postal Code: | 02494 |
| Exchange: | NSD |
| CEO: | Robert Forrester |
| Employees: | 169 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
| Last Price 1.40 | Change $ 0.13 | Change % 10.24 | Tick N/A |
| Bid 1.36 | Bid Size 500.00 | Ask 1.42 | Ask Size 2,200.00 |
| Open 1.26 | High 1.45 | Low 1.25 | Prev Close 1.27 |
| Last Trade | Volume 2.8 mi | 52 Wk Hi 10.35 | 52 Wk Low 1.16 |
| Market Cap 103.4 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 73,876,939.00 | EPS (TTM) -1.49 | PE Ratio N/A | Exchange NSD |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 2 | 3 |
| Number of Buys | 2 | 3 |
| Number of Sells | 0 | 0 |
| Net Activity | 10700 | 71238 |
| Last 10 Buys | Shares |
|---|---|
| Steven H. Bloom | 1,000 |
| Joseph M. Lobacki | 1,000 |
| Timothy J. Barberich | 1,000 |
| Timothy J. Barberich | 1,000 |
| Monica Kleinman | 1,000 |
| John B. Green | 1,000 |
| Robert Forrester | 1,000 |
| John B. Green | 1,000 |
| Daniel Paterson | 1,000 |
| Robert Forrester | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| N/A | 0 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 17 | 17 | 17 | 17 |
| Low Target Price Estimate | 7 | 7 | 7 | 7 |
| Mean Target Price Estimate | 13.14 | 13.14 | 13.14 | 13.14 |
| Standard Deviation | 3.72 | 3.72 | 3.72 | 3.72 |
| Date of Most Recent Estimate | 05/31/18 | 05/22/18 | 05/22/18 | 05/31/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 424B5 | Prospectus filed under Rule 424(b)(5) | 39 | 2018-06-14 |
| S-3MEF | Registration of up to an additional 20% of securities for any offering registered on a S-3 | 7 | 2018-06-14 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-12 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-12 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-06-08 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-04 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-04 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-04 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-04 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-04 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 6 | 6 | 5 | 5 |
| Moderate Buy | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.14 | 1.14 | 1.17 | 1.17 |
© 2019 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
